Purified, activated immune cells from a healthy donor are injected into the recipient until the immune system can hunt down cancer cells on its own
Could an immunotherapy treatment from Israel cure cancer?
Ten years ago, Dr. Michael Har-Noy, founder and CEO of a Jerusalem-based startup developing an immunotherapy treatment that could potentially cure cancer, lamented that the fight against the dreaded disease “is a battle we are losing.” Today, Har-Noy’s company is getting closer to turning the tide.
In the past decade, Immunovative Therapies has conducted dozens of clinical trials, opened branches in California, Arizona and Thailand, and raised $35 million.
But the biggest boost came from the publicity surrounding immunotherapy pioneer Jim Allison, who won this year’s Nobel Prize in chemistry.
Ten years ago, “We couldn’t get a venture capitalist to open a business plan if they saw the words ‘immunotherapy.’ They’d say, ‘That doesn’t work in cancer,’” Har-Noy tells ISRAEL21c.
Following Allison’s work that proved immunotherapy’s efficacy, “anyone with ‘immune’ in their name is now able to raise funds,” Har-Noy says.
Indeed, consulting firm Transparency Market Research predicts that the global market value of cancer immunotherapy drugs will reach $124 billion by 2024. --
MORE...
ISRAEL21c -- Bio and
Archives |
Comments
ISRAEL21c was founded in 2001, in the wake of the Second Intifada, to broaden public understanding of Israel beyond typical portrayals in the mainstream media.
The organization’s founders – Israeli-American technology executives – understood the great power of the Internet and developed a first-of-its kind online product with global appeal and reach.
